您当前的位置:
首页 >
文章列表页 >
Risk Identification and Evaluation of Clinical Trials of I nnovative Drugs under New Policy Environment
更新时间:2022-06-21
    • Risk Identification and Evaluation of Clinical Trials of I nnovative Drugs under New Policy Environment

    • China Pharmacy   Vol. 32, Issue 10, (2021)
    • Published:2021

    扫 描 看 全 文

  • AN Xiaoling, HUANG Wenqiang, SU Yunan, et al. Risk Identification and Evaluation of Clinical Trials of I nnovative Drugs under New Policy Environment. [J]. China Pharmacy 32(10).(2021) DOI:

  •  
  •  

0

Views

20

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

2000-2012年江苏省医药制造业产业集群发展研究
CCA法与FMEA法在制药纯化水分配系统风险评估中的应用
FTA法与FMECA法在药品质量偏差调查中的应用
Differences Analysis of Chemical Composition of Raw and Fried Glycyrrhiza uralensis Based on UPLC-Q-TOF- MS

Related Author

虞巧巧 邱家学
梁毅 丁恩伟
TAN Hongyu
SHAN Huafeng
LI Tianzhu
WANG Yu
CHEN Jingchao
CUI Yuanyuan

Related Institution

No data
0